Biology subjects

Burrows, A. C.

Publications and source records attributed to Burrows, A. C..

4 recordsLinked to original sources

bioRxiv2026

Per-and polyfluoroalkyl substances (PFAS) driven reorganization of brain metabolism is impacted by resident microbiota

BackgroundEmerging evidence suggests that PFAS can cross blood-brain barrier and lead to neurotoxicity. Recent evidence also suggest that PFAS can bioaccumulate in gut microbiota resident in the gut. However, how gut microbes influence PFAS-driven reorganization of metabolic homeostasis in the brain is poorly understood. MethodsTo address this gap, we investigated how gut microbiota influences brain metabolomic and lipidomic responses to PFAS exposure. Specific pathogen-free (SPF) and germ-free (GF) mice were fed an obesogenic diet for 8 weeks to promote metabolic disturbance. After 1 week of acclimation, half received control water and half received water containing a PFAS mixture (PFHxS, GenX, PFOA, PFOS, and FTOH mixture). Plasma and brain samples (cortex, subcortex, cerebellum, olfactory bulb, and brainstem) were collected after 8 weeks. Untargeted analyses were performed for lipidomic, metabolomic and PFAS using high resolution liquid chromatography tandem mass spectrometry (LC-MS/MS). Data was processed using MassCube with open-sources libraries. ResultsPFHxS, GenX, PFOA, PFOS, PFDA, and PFDS were detected in plasma. PFHxS, PFOA, PFOS, and PFDS were detected across all five brain regions, with PFOS as the predominant brain-enriched species. Pathway analysis identified nicotinate and nicotinamide metabolism as the most consistently PFAS-altered pathway in both SPF and GF mice. PFAS exposure induced region-specific metabolic remodeling, with gut microbiota differentially modulating responses in the cortex, cerebellum, and brainstem, whereas the olfactory bulb showed a largely microbiota-independent response. In addition to local effects within individual brain regions, plasma-brain analysis suggested systemic metabolic responses across tissues, with association strength varying by brain region and microbiome status. Gut microbiota also shaped PFAS-induced lipid dysregulation in the brain, and methylnicotinamide and delta-valerobetaine were among the most responsive metabolites. ConclusionThis study is the first to demonstrate that resident microbiota impact PFAS-associated metabolic remodeling across the gut-plasma-brain axis. HighlightsO_LIPFAS-induced metabolic remodeling in the brain is modified by gut microbiota. C_LIO_LIPFAS exposure alters nicotinate and nicotinamide metabolism throughout the brain. C_LIO_LIPFAS-induced brain metabolic responses are region specific and microbiota dependent. C_LIO_LIPlasma-brain analysis suggests potential systemic metabolic disruption by PFAS. C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/743341v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@15301deorg.highwire.dtl.DTLVardef@9fac0aorg.highwire.dtl.DTLVardef@d7f0f4org.highwire.dtl.DTLVardef@10c29c2_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗

bioRxiv2026

Multi-Omic Analyses of Dietary Fatty Acid-Microbe-Host Interactions Reveal Metaorganismal Lipid Metabolic Crosstalk Impacting Cardiometabolic Disease

Following a meal, our gut microbiome and human cells collaborate via metaorganismal metabolic circuits to produce diverse nutrient metabolites that systemically circulate to influence health and disease. Although there are now several examples of bacterial fiber-, amino acid-, and micronutrient-derived metabolites impacting cardiometabolic disease, very little is known in regards to how diet-microbe-host interactions impact lipid homeostasis. Here we address this by defining dietary fatty acid substrate availability in germ-free versus conventionally-raised mice coupled to deep multi-omic metabolic phenotyping. Our data demonstrate that the effects of dietary saturated (SFA), monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) on the host lipidome, transcriptome, proteome and metabolome are uniquely impacted by resident microbiota. Also, the hepatic levels of both pro-inflammatory and pro-resolving lipid mediators are strongly influenced by dietary fatty acid-microbe interactions. This study presents a unique resource to the nutrition and metabolism research community to advance our understanding of metaorganismal lipid metabolism. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/705588v1_ufig1.gif" ALT="Figure 1"> View larger version (50K): org.highwire.dtl.DTLVardef@4fc7e3org.highwire.dtl.DTLVardef@1cc1dc8org.highwire.dtl.DTLVardef@1b7648dorg.highwire.dtl.DTLVardef@12a8088_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGRAPHICAL ABSTRACTC_FLOATNO C_FIG

biochemistry↗

bioRxiv2025

The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma

Primary liver cancer accounts for approximately 700,000 deaths worldwide annually ranking third in cancer-related mortality, with hepatocellular carcinoma (HCC) comprising the majority of these tumors. Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a leading cause of HCC in the United States. We previously identified the lipid hydrolase alpha/beta hydrolase domain 6 (ABHD6) as a key mediator of the development of metabolic syndrome and intimately involved in cell signaling, making it a prime target for investigation in MASLD-related HCC. ABHD6 displays higher expression within HCC tumor cores when compared to adjacent non-tumor liver tissue in human subjects. Using an in vivo antisense oligonucleotide (ASO)-driven knockdown approach, we have shown the inhibition of ABHD6 prevents the development and progression of HCC in an obesity/MASLD-driven mouse model. Additionally, a xenograft model using the human Huh7 cell line displayed reduced tumor engraftment and growth with ABHD6 genetic deletion and small molecule inhibition. ABHD6 knockout cells demonstrated increased levels of bis(monoacylglycerol)phosphates (BMPs), lipids relevant to high fat diet-induced lysosomal dysfunction, and knockout cells also demonstrated altered autophagy and lysosomal activity using in vitro model of saturated fatty acid-induced lipotoxicity. These studies reveal novel lipid signaling mechanisms by which MASLD progresses towards HCC and provide support for ABHD6 as a therapeutic target in HCC. SignificanceWe have identified that alpha/beta hydrolase domain 6 (ABHD6) plays a role in lysosomal membrane lipid remodeling pathways that are relevant in obesity/MASLD-driven HCC. Inhibitors targeting ABHD6 reorganize lysosomal lipid homeostasis to improve outcomes in HCC.

cancer biology↗

bioRxiv2019

The Deubiquitinating Enzyme USP37 Stabilizes CHK1 to Promote the Cellular Response to Replication Stress

The deubiquitinating enzyme USP37 is known to contribute to timely S-phase onset. However, it is not clear if USP37 is essential beyond S-phase entry despite expression and activity of USP37 peaking within S-phase. Here, we determine that USP37-depleted cells exhibited altered S-phase kinetics and harbored increased levels of the replication stress and DNA damage markers {gamma}H2AX and 53BP1 in response to perturbed replication. Depletion of USP37 also reduced cellular proliferation and led to increased sensitivity to agents that induce replication stress. Underlying the increased sensitivity, we found that the checkpoint kinase CHK1 is destabilized in the absence of USP37, attenuating its function. We further demonstrated that USP37 deubquitinates and stabilizes CHK1. Our data contribute to an evolving understanding of UPS37 as a multifaceted regulator of genome regulation.

cell biology↗